Qualigen Therapeutics provides update on developments at NanoSynex

Qualigen Therapeutics shares an update on its majority-owned subsidiary, NanoSynex, the progress made during 2022, and objectives for 2023 concerning the commercialization plans for its innovative rapid Antimicrobial Susceptibility Test. The update comes in the form of a letter provided to NanoSynex’s shareholders, including Qualigen, from its CEO, Diane Abensur: "The year 2022 was very productive, with several key milestones reached. In short, we are on track and within budget towards our ultimate objective of launching our Antimicrobial Susceptibility Test and are poised to have another momentous year ahead in the execution of our milestones… We are looking forward to accomplishing the following key milestones in 2023: Development, design, and manufacture of the product for which we will seek CE approval to launch commercially; Obtaining ISO certification; Commencing final clinical studies to obtain CE mark; and Continuing dissemination efforts through presence in leading conferences, including product demonstration, scientific abstracts submission and featuring in key media channels. We believe it is important to keep in mind why NanoSynex is working towards this goal of commercializing this AST, which may provide critical results to be both significantly faster and more accurate than current microbial tests performed in hospitals, potentially saving many lives, and reducing the economic healthcare burden."